Venous Thromboembolism Treatment Market By Type 2022 | IndustryARC
  • 1-614-588-8538 (Ext: 101)
  • US Toll Free

Venous Thromboembolism Treatment Market
Venous Thromboembolism Treatment Market: By Type (Deep Venous Thrombosis, and Pulmonary Embolism); By Treatment (Heparin, Apixaban, Dabigatran, Rivaroxaban, Edaxaban, Others) & By Region (Europe, North America, Asia-Pacific, RoW)-Forecast (2016-2022)
Report Code : HCR 0688
Updated Date: 27 September, 2016  

  • Report Description
  • Table of Contents
  • Customization Options
1. Venous Thromboembolism Treatment Market – Overview
2. Executive Summary
3. Venous Thromboembolism Treatment Market Landscape

   3.1. Market Share Analysis
   3.2. Comparative Analysis
   3.3. Product Benchmarking
   3.4. End User Profiling
   3.5. Top 5 Financials Analysis
4. Venous Thromboembolism Treatment Market– Forces
   4.1. Drivers
      4.1.1. Development of efficient and advance technology
      4.1.2. Growing prevalence and incidence rate of venous thromboembolism
   4.2. Restraints
      4.2.1. Higher cost of research and development
   4.3. Opportunities
      4.3.1. Emerging economies
   4.4. Challenges
   4.5. Porter’s Five Forces Analysis
      4.5.1. Bargaining Power of Suppliers
      4.5.2. Bargaining Power of Buyers
      4.5.3. Threat of New Entrants
      4.5.4. Threat of Substitutes
      4.5.5. Degree of Competition
5. Venous Thromboembolism Treatment Market– Strategic Analysis
   5.1. Value Chain Analysis
   5.2. Pricing Analysis
   5.3. Opportunities Analysis
   5.4. Product/Market Life Cycle Analysis
   5.5. Suppliers and Distributors
6. Venous Thromboembolism Treatment Market, By Type
   6.1. Deep Venous Thrombosis
   6.2. Pulmonary Embolism
7. Venous Thromboembolism Treatment Market, By Treatment
   7.1. Heparin
   7.2. Apixaban
   7.3. Dabigatran
   7.4. Rivaroxaban
   7.5. Edaxaban
   7.6. Warfarin
   7.7. Compression Therapy
   7.8. Inferior Vena Cava Filter
   7.9. Thrombolytic Therapy
8. Venous Thromboembolism Treatment Market, By Geography
   8.1. Europe
      8.1.1. Germany
      8.1.2. France
      8.1.3. Italy
      8.1.4. Spain
      8.1.5. Russia
      8.1.6. U.K.
      8.1.7. Rest of Europe
   8.2. Asia Pacific
      8.2.1. China
      8.2.2. India
      8.2.3. Japan
      8.2.4. South Korea
      8.2.5. Rest of Asia-Pacific
   8.3. North America
      8.3.1. U.S.
      8.3.2. Canada
      8.3.3. Mexico
   8.4. Rest of the World (RoW)
      8.4.1. Brazil
      8.4.2. Rest of RoW
9. Venous Thromboembolism Treatment Market – Entropy
   9.1. Expansion
   9.2. Technological Developments
   9.3. Merger & Acquisitions, and Joint Ventures
   9.4. Supply- Contract
10. Company Profiles (Overview, Financials, SWOT Analysis, Developments, Product Portfolio)
   10.1. Abbott Laboratories
   10.2. Bio Compression Systems, Inc.
   10.3. Boehringer Ingelheim GmbH
   10.4. Upsher-Smith Laboratories,Inc
   10.5. Bristol-Myers Squibb Company
   10.6. Merck & Co.
   10.7. Dupont Pharm Co
   10.8. Wockhardt Ltd
   10.9. Bayer AG
   10.10. Pfizer Inc.
*More than 40 Companies are profiled in this Research Report, Complete List available on Request*
"*Financials would be provided on a best efforts basis for private companies"
11. Appendix

   11.1. Abbreviations
   11.2. Sources
   11.3. Research Methodology
   11.4. Bibliography
   11.5. Compilation of Expert Insights
   11.6. Disclaimer
Venous Thromboembolism (VTE) is a lethal disorder that affects the hospitalized and non-hospitalized patients, recurs frequently, and results in long-term complications including chronic thromboembolic pulmonary hypertension (CTPH) and the post-thrombotic syndrome (PTS). It includes both deep vein thrombosis (DVT) and pulmonary embolism (PE). Globally, development of efficient and advanced technology, rise in the awareness among people regarding existing treatments for venous thromboembolism, increasing government initiatives across the globe, growing prevalence and incidence rate of venous thromboembolism are the prime growth drivers of the venous thromboembolism treatment market. In addition, an increase in adoption of venous thromboembolism treatment in emerging economies such as China, India and others, will create new opportunities for the venous thromboembolism treatment market. However, higher cost of the research and development, and complex government regulatory approvals are the key restraints for the venous thromboembolism treatment market.

 Venous Thromboembolism Treatment Market

Geographically, North America dominated the venous thromboembolism treatment market, because of high medical reimbursement facilities, and technological advancement. Asia Pacific is projected to have the fastest growth, owing to a rapidly increasing population, rise in consumer awareness, favourable government policies, modernization of healthcare infrastructure, and growing medical tourism industry in developing nations such as China, and India in this region. Among all the types, deep vein thrombosis (DVT) has the highest market share in the venous thromboembolism treatment market.

This report identifies the venous thromboembolism treatment market size for the years 2014-2016, and forecast of the same till the year 2022. It also highlights the market drivers, restraints, growth indicators, challenges, and other key aspects with respect to the venous thromboembolism treatment market.

This report segments the venous thromboembolism treatment market on the basis of type, treatment, and regional market as follows:
  • Venous Thromboembolism Treatment Market, By Type: Deep Venous Thrombosis, and Pulmonary Embolism
  • The report has focused study on venous thromboembolism treatment market by basis of treatment such as: Heparin, Apixaban, Dabigatran, Rivaroxaban, Edaxaban, Warfarin, Compression Therapy, Inferior Vena Cava Filter, and Thrombolytic Therapy
  • This report has been further segmented into major regions, which includes detailed analysis of each region such as: North America, Europe, Asia-Pacific (APAC), and Rest of the World (RoW) covering all the major country level markets in each of the region

This report identifies all the major companies operating in the venous thromboembolism treatment market. Some of the major companies’ profiles in detail are as follows:
  • Abbott Laboratories
  • Bio Compression Systems, Inc.
  • Boehringer Ingelheim GmbH
  • Upsher-Smith Laboratories,Inc
  • Bristol-Myers Squibb Company
Please select Licence
Single User Licence:
US $4250
Corporate User Licence:
US $6250
Related Reports